Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Ludwig, H.; Van Belle, S.; Barrett-Lee, P.; Birgegård, G.; Bokemeyer, C.; Gascón, P.; Kosmidis, P.; Krzakowski, M.; Nortier, J.; Olmi, P.; et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur. J. Cancer 2004, 40, 2293–2306. [Google Scholar] [CrossRef] [PubMed]
- Varlotto, J.; Stevenson, M.A. Anemia, tumor hypoxemia, and the cancer patient. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63, 25–36. [Google Scholar] [CrossRef] [PubMed]
- Family, L.; Xu, L.; Xu, H.; Cannavale, K.; Sattayapiwat, O.; Page, J.H.; Bohac, C.; Chao, C. The effect of chemotherapy-induced anemia on dose reduction and dose delay. Support. Care Cancer 2016, 24, 4263–4271. [Google Scholar] [CrossRef] [PubMed]
- Caro, J.J.; Salas, M.; Ward, A.; Goss, G. Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer 2001, 91, 2214–2221. [Google Scholar] [CrossRef]
- Gluszak, C.; de Vries-Brilland, M.; Seegers, V.; Baroin, C.; Kieffer, H.; Delva, R.; Cornuault-Foubert, D. Impact of Iron-Deficiency Management on Quality of Life in Patients with Cancer: A Prospective Cohort Study (CAMARA Study). Oncologist 2022, 27, 328–333. [Google Scholar] [CrossRef]
- Madeddu, C.; Gramignano, G.; Astara, G.; Demontis, R.; Sanna, E.; Atzeni, V.; Macciò, A. Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach. Front. Physiol. 2018, 9, 1294. [Google Scholar] [CrossRef]
- Neoh, K.; Stanworth, S.; Pasricha, S.-R.; Bennett, M.I. Estimating prevalence of functional iron deficiency anaemia in advanced cancer. Support. Care Cancer 2017, 25, 1209–1214. [Google Scholar] [CrossRef]
- de Castro, J.; Gascón, P.; Casas, A.; Muñoz-Langa, J.; Alberola, V.; Cucala, M.; Barón, F. Iron deficiency in patients with solid tumours: Prevalence and management in clinical practice. Clin. Transl. Oncol. 2014, 16, 823–828. [Google Scholar] [CrossRef]
- Ludwig, H.; Müldür, E.; Endler, G.; Hübl, W. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann. Oncol. 2013, 24, 1886–1892. [Google Scholar] [CrossRef]
- Buck, I.; Morceau, F.; Grigorakaki, C.; Dicato, M.; Diederich, M. Linking anemia to inflammation and cancer: The crucial role of TNFα. Biochem. Pharmacol. 2009, 77, 1572–1579. [Google Scholar] [CrossRef]
- Hoenemann, C.; Ostendorf, N.; Zarbock, A.; Doll, D.; Hagemann, O.; Zimmermann, M.; Luedi, M. Reticulocyte and Erythrocyte Hemoglobin Parameters for Iron Deficiency and Anemia Diagnostics in Patient Blood Management. A Narrative Review. J. Clin. Med. 2021, 10, 4250. [Google Scholar] [CrossRef] [PubMed]
- Girelli, D.; Nemeth, E.; Swinkels, D.W. Hepcidin in the diagnosis of iron disorders. Blood 2016, 127, 2809–2813. [Google Scholar] [CrossRef] [PubMed]
- Steensma, D.P.; Sasu, B.J.; Sloan, J.A.; Tomita, D.K.; Loprinzi, C.L. Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia. Blood 2015, 125, 3669–3671. [Google Scholar] [CrossRef] [PubMed]
- Aapro, M.; Beguin, Y.; Bokemeyer, C.; Dicato, M.; Gascón, P.; Glaspy, J.; Hofmann, A.; Link, H.; Littlewood, T.; Ludwig, H.; et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann. Oncol. 2018, 29, iv96–iv110. [Google Scholar] [CrossRef] [PubMed]
- Anker, S.D.; Comin Colet, J.; Filippatos, G.; Willenheimer, R.; Dickstein, K.; Drexler, H.; Lüscher, T.F.; Bart, B.; Banasiak, W.; Niegowska, J.; et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N. Engl. J. Med. 2009, 361, 2436–2448. [Google Scholar] [CrossRef]
- Kulnigg, S.; Stoinov, S.; Simanenkov, V.; Dudar, L.V.; Karnafel, W.; Garcia, L.C.; Sambuelli, A.M.; D’Haens, G.; Gasche, C. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: The ferric carboxymaltose (FERINJECT) randomized controlled trial. Am. J. Gastroenterol. 2008, 103, 1182–1192. [Google Scholar] [CrossRef]
- Macdougall, I.C.; Bock, A.H.; Carrera, F.; Eckardt, K.-U.; Gaillard, C.; Van Wyck, D.; Roubert, B.; Nolen, J.G.; Roger, S.D.; on behalf of the FIND-CKD Study Investigators. FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol. Dial. Transplant. 2014, 29, 2075–2084. [Google Scholar] [CrossRef]
- Keeler, B.D.; Simpson, J.A.; Ng, O.; Padmanabhan, H.; Brookes, M.J.; Acheson, A.G.; Banerjea, A.; Walter, C.; Maxwell-Armstrong, C.; Williams, J.; et al. Randomized clinical trial of preoperative oral versus intravenous iron in anaemic patients with colorectal cancer. Br. J. Surg. 2017, 104, 214–221. [Google Scholar] [CrossRef]
- Steinmetz, T.; Tschechne, B.; Harlin, O.; Klement, B.; Franzem, M.; Wamhoff, J.; Tesch, H.; Rohrberg, R.; Marschner, N. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann. Oncol. 2013, 24, 475–482. [Google Scholar] [CrossRef]
- Jang, J.H.; Kim, Y.; Park, S.; Kim, K.; Kim, S.J.; Kim, W.S.; Jung, C.W.; Lee, J.; Lee, S.H. Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea. PLoS Med. 2020, 17, e1003091. [Google Scholar] [CrossRef]
- Toledano, A.; Luporsi, E.; Morere, J.F.; Scotté, F.; Laribi, K.; Barrière, J.; Huot-Marchand, P.; Duvillié, L.; Concas, V.H.; Bugat, R. Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France. Support. Care Cancer 2016, 24, 67–75. [Google Scholar] [CrossRef] [PubMed]
- Verhaeghe, L.; Bruyneel, L.; Stragier, E.; Ferrante, M.; Dierickx, D.; Prenen, H. The effectiveness of intravenous iron for iron deficiency anemia in gastrointestinal cancer patients: A retrospective study. Ann. Gastroenterol. 2017, 30, 654–663. [Google Scholar] [CrossRef] [PubMed]
- Makharadze, T.; Boccia, R.; Krupa, A.; Blackman, N.; Henry, D.H.; Gilreath, J.A. Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo-controlled study (IRON-CLAD). Am. J. Hematol. 2021, 96, 1639–1646. [Google Scholar] [CrossRef]
- Abdel-Razeq, H.; Saadeh, S.S.; Malhis, R.; Yasser, S.; Abdulelah, H.; Eljaber, R.; Kleib, A.; Ismael, R. Treatment of anemia in cancer patients undergoing chemotherapy with intravenous ferric carboxymaltose without erythropoiesis-stimulating agents. Ther. Adv. Med. Oncol. 2020, 12, 1758835920953292. [Google Scholar] [CrossRef] [PubMed]
- Talboom, K.; Borstlap, W.A.A.; Roodbeen, S.X.; Bruns, E.R.J.; Buskens, C.J.; Hompes, R.; Tytgat, K.M.A.J.; Tuynman, J.B.; Consten, E.C.J.; Heuff, G.; et al. Ferric carboxymaltose infusion versus oral iron supplementation for preoperative iron deficiency anaemia in patients with colorectal cancer (FIT): A multicentre, open-label, randomised, controlled trial. Lancet Haematol. 2023, 10, e250–e260. [Google Scholar] [CrossRef]
- Abdel-Razeq, H.; Abbasi, S.; Saadi, I.; Jaber, R.; Abdelelah, H. Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: A pilot study. Drug Des. Dev. Ther. 2013, 7, 939–944. [Google Scholar] [CrossRef] [PubMed]
- Laso-Morales, M.J.; Vives, R.; Bisbe, E.; García-Erce, J.A.; Muñoz, M.; Martínez-López, F.; Carol-Boeris, F.; Pontes-García, C. Single-dose intravenous ferric carboxymaltose infusion versus multiple fractionated doses of intravenous iron sucrose in the treatment of post-operative anaemia in colorectal cancer patients: A randomised controlled trial. Blood Transfus. 2022, 20, 310–318. [Google Scholar] [CrossRef]
- Bach, M.; Geisel, T.; Martin, J.; Schulze, B.; Schaefer, R.; Virgin, G.; Stein, J. Efficacy and Safety of Intravenous Ferric Carboxymaltose in Geriatric Inpatients at a German Tertiary University Teaching Hospital: A Retrospective Observational Cohort Study of Clinical Practice. Anemia 2015, 2015, 647930. [Google Scholar] [CrossRef]
- Ning, S.; Zeller, M.P. Management of iron deficiency. Hematology 2019, 2019, 315–322. [Google Scholar] [CrossRef]
- Calleja, J.L.; Delgado, S.; del Val, A.; Hervás, A.; Larraona, J.L.; Terán, Á.; Cucala, M.; Mearin, F.; on behalf of the Colon Cancer Study, G. Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. Int. J. Color. Dis. 2016, 31, 543–551. [Google Scholar] [CrossRef]
- Marinho, J.; Leão, I.; Custódio, S.; Dias, E.; Moreira Pinto, A.; Costa, T.; Capela, A.; Dias, M.; Coelho, H.; Cunha, Â.; et al. Ferric Carboxymaltose in the treatment of chemotherapy-induced anaemia: An effective, safe and cost- sparing alternative to blood transfusion. Sci. Rep. 2019, 9, 20410. [Google Scholar] [CrossRef]
- Nemeth, E.; Tuttle, M.S.; Powelson, J.; Vaughn, M.B.; Donovan, A.; Ward, D.M.; Ganz, T.; Kaplan, J. Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization. Science 2004, 306, 2090–2093. [Google Scholar] [CrossRef] [PubMed]
- Brugnara, C.; Schiller, B.; Moran, J. Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states. Clin. Lab. Haematol. 2006, 28, 303–308. [Google Scholar] [CrossRef]
- Sasu, B.J.; Li, H.; Rose, M.J.; Arvedson, T.L.; Doellgast, G.; Molineux, G. Serum hepcidin but not prohepcidin may be an effective marker for anemia of inflammation (AI). Blood Cells Mol. Dis. 2010, 45, 238–245. [Google Scholar] [CrossRef] [PubMed]
- Drakou, A.; Margeli, A.; Theodorakopoulou, S.; Agrogiannis, I.; Poziopoulos, C.; Papassotiriou, I.; Vlahakos, D.V. Assessment of serum bioactive hepcidin-25, soluble transferrin receptor and their ratio in predialysis patients: Correlation with the response to intravenous ferric carboxymaltose. Blood Cells Mol. Dis. 2016, 59, 100–105. [Google Scholar] [CrossRef] [PubMed]
- Hershko, C.; Camaschella, C. How I treat unexplained refractory iron deficiency anemia. Blood 2014, 123, 326–333. [Google Scholar] [CrossRef]
- Grimmelt, A.C.; Cohen, C.D.; Fehr, T.; Serra, A.L.; Wuethrich, R.P. Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Clin. Nephrol. 2009, 71, 125–129. [Google Scholar] [CrossRef] [PubMed]
- Decruyenaere, A.; Kortbeek, K.; Delanghe, S.; Rottey, S.; Denys, H.; Lapeire, L. Incidence, evolution and risk factors of hypophosphatemia in patients with solid tumors receiving ferric carboxymaltose: A retrospective cohort study. Acta Clin. Belg. 2023, 78, 298–307. [Google Scholar] [CrossRef]
N = 1102 | |
---|---|
Age (years, median (Q1–Q3)) | 60 (48–68) |
Female, n (%) | 696 (63.2%) |
Cancer type, n (%) | |
Gastrointestinal | 510 (46.3%) |
Breast | 319 (28.9%) |
Genitourinary | 76 (6.9%) |
Lung | 48 (4.4%) |
Gynecological | 35 (3.2%) |
Hematological | 31 (2.8%) |
Head and Neck | 25 (2.3%) |
Other | 58 (5.3) |
Active chemotherapy, n (%) | 870 (78.9%) |
Anemia Grade n (%) | |
1 | 764 (69.3%) |
2 | 306 (27.8%) |
3 | 32 (2.9%) |
N = 1102 | |
---|---|
Baseline hemoglobin | |
Mean (SD) | 10.4 (±1.1) g/dL |
Median (Q1–Q3) | 10.7 (9.7–11.4) |
Leucocyte (Median (Q1–Q3)) | 6200 (4400–8100) |
Thrombocyte (Median (Q1–Q3)) | 295,000 (220,000–382,000) |
Ferritin (Median (Q1–Q3)) | 23.7 (16.7–37.8) |
Transferrin saturation (Median (Q1–Q3)) | 8 (5–12) |
Week-12 hemoglobin | |
Mean (SD) | 12.2 (±1.4) g/dL |
Median (Q1–Q3) | 12.3 (11.3–13.3) |
Δ hemoglobin | |
Mean (SD) | 1.81 (±0.14) g/dL |
Median (Q1–Q3) | 1.60 (0.8–2.8) |
Treatment Response, % (Increase in Hb ≥ 1 g/dL) | 794 (72.1%) |
Δ Hemoglobin (±SD), g/dL | p | Response Rate, % | p | |
---|---|---|---|---|
Gender | 0.87 | 0.018 | ||
Female | 1.81 (±1.27) | 74.5% | ||
Male | 1.79 (±1.62) | 67.7% | ||
Age | 0.35 | 0.70 | ||
<65 | 1.83 (±1.41) | 72.4% | ||
≥65 | 1.75 (±1.41) | 71.4% | ||
Tumor Type | 0.67 | 0.41 | ||
Gastrointestinal | 1.76 (±1.32) | 72.9% | ||
Breast | 1.83 (±1.48) | 69.9% | ||
Genitourinary | 1.63 (±1.49) | 68.4% | ||
Lung | 2.09 (±1.67) | 77.0% | ||
Gynecological | 1.92 (±1.29) | 74.2% | ||
Hematological | 1.73 (±1.66) | 61.2% | ||
Head and Neck | 2.6 (±1.23) | 88.5% | ||
Other | 1.81 (±1.88) | 74.1% | ||
Anemia Grade | <0.005 | <0.005 | ||
Grade 1 | 1.52 (±1.24) | 68.1% | ||
Grade 2 | 2.39 (±1.53) | 79.4% | ||
Grade 3 | 3.06 (±1.66) | 93.7% | ||
Active Treatment | 0.04 | 0.24 | ||
Yes | 1.74 (±1.30) | 72.9% | ||
No | 2.01 (±1.73) | 69.0% |
N = 510 | |
---|---|
Age (years, median (Q1–Q3)) | 57 (45–68) |
Female, n (%) | 252 (49.4%) |
Cancer type, n (%) | |
Upper GI | 147 (28.8%) |
HPB | 80 (15.7%) |
Lower GI | 283 (55.5%) |
Active chemotherapy, n (%) | 423 (82.9%) |
Baseline hemoglobin | |
Mean (SD) | 10.4 (±1.7) g/dL |
Median (Q1–Q3) | 10.7 (9.8–11.4) |
Δ hemoglobin | |
Mean (SD) | 1.76 (±0.34) g/dL |
Median (Q1–Q3) | 1.60 (0.9–2.7) |
Treatment response, % (increase in Hb ≥ 1 g/dL) | 372 (72.9%) |
Δ Hemoglobin (±SD), g/dL | p | Response Rate, % | p | |
---|---|---|---|---|
Gender | 0.81 | 0.21 | ||
Female | 1.77 (±1.22) | 74.6% | ||
Male | 1.74 (±1.52) | 69.2% | ||
Age | 0.87 | 0.54 | ||
<65 | 1.77 (±1.35) | 72.1% | ||
≥65 | 1.75 (±1.26) | 74.6% | ||
Tumor Location | 0.91 | 0.40 | ||
Upper GI | 1.80 (±1.36) | 72.1% | ||
HPB | 1.78 (±1.32) | 67.5% | ||
Lower GI | 1.74 (±1.30) | 74.9% | ||
Active Treatment | 0.03 | 0. 04 | ||
Yes | 1.71 (±1.25) | 72.9% | ||
No | 2.04 (±1.57) | 84.0% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Aktaş, B.Y.; Ata, E.B.; Çeşmeci, E.; Çakır, İ.Y.; Coşkunpınar, M.; Tahillioğlu, Y.; Güner, G.; Güven, D.C.; Arık, Z.; Kertmen, N.; et al. Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia. Curr. Oncol. 2023, 30, 9689-9700. https://doi.org/10.3390/curroncol30110703
Aktaş BY, Ata EB, Çeşmeci E, Çakır İY, Coşkunpınar M, Tahillioğlu Y, Güner G, Güven DC, Arık Z, Kertmen N, et al. Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia. Current Oncology. 2023; 30(11):9689-9700. https://doi.org/10.3390/curroncol30110703
Chicago/Turabian StyleAktaş, Burak Yasin, Emine Büşra Ata, Engin Çeşmeci, İbrahim Yahya Çakır, Muharrem Coşkunpınar, Yağmur Tahillioğlu, Gürkan Güner, Deniz Can Güven, Zafer Arık, Neyran Kertmen, and et al. 2023. "Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia" Current Oncology 30, no. 11: 9689-9700. https://doi.org/10.3390/curroncol30110703
APA StyleAktaş, B. Y., Ata, E. B., Çeşmeci, E., Çakır, İ. Y., Coşkunpınar, M., Tahillioğlu, Y., Güner, G., Güven, D. C., Arık, Z., Kertmen, N., Dizdar, Ö., Yalçın, Ş., & Aksoy, S. (2023). Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia. Current Oncology, 30(11), 9689-9700. https://doi.org/10.3390/curroncol30110703